Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
NVIDIA Announces Upcoming Events for Financial Community
-
Accent Therapeutics to Present Trial in Progress Poster for Phase 1/2 Study of ATX-295 at the 2026 American Society of Clinical Oncology Annual Meeting
-
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
-
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
-
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
-
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
-
WhiteFiber Signs AI Compute Agreement with Total Contract Value in Excess of $160 Million with Investment-Grade Technology Customer
-
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
-
Greenberg Traurig Bolsters Government Contracts and Space Practices with Shaun Kennedy in Denver
-
Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026
-
New Clinical Data for Izalontamab Brengitecan and Novel ADC Pipeline to be Presented at ASCO 2026
-
Navient declares second quarter common stock dividend
-
Dell Technologies to Present at Investor Conference in June
-
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2
-
Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
-
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
-
A2 Biotherapeutics Presents Safety and Efficacy Data from the EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with Non-Small Cell Lung Canc
-
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
-
858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting
-
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer
-
Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting
-
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
-
Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio
-
Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026
-
Marriott International and The Fern Hotels & Resorts Celebrate 75 Signings and 50 Openings for Series by Marriott in India
-
Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026
-
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
-
Legend Biotech Announces Presentations at ASCO 2026
-
Ingenia Therapeutics, a Clinical-Stage Biotechnology Company, Has Received Approval for an Initial Public Offering on the Korea Exchange (KRX)
-
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
-
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
-
City of Hope Researchers Present Advances in Targeted Therapies, Microbiome Science and Blood Cancers at ASCO 2026
-
Boehringer Ingelheim's oncology portfolio shows strong promise across multiple cancers at ASCO 2026
-
Sapience Therapeutics Provides Positive Data Update from Phase 2 Trial of Lucicebtide Plus SOC in Patients with Glioblastoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
-
Revival Gold Announces Adoption of Shareholder Rights Plan and Corporate Update
-
Silver Wolf Adopts Semi-Annual Financial Reporting
-
SuperBuzz Announces Adoption of Semi-Annual Reporting and CFO Transition
-
Chinese and International Cultural Figures Explores Heritage and Innovation in China's Hubei Province
-
Tigé Boats Signs Professional Wakesurfer Parker Payne
-
Sagrada Família to Inaugurate Tower of Jesus Christ on June 10, 2026, Marking 100 Years Since Antoni Gaudí's Death
-
NexGen Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders
-
Banco Comercial Português, S.A., announces the commencement of duties of the Board of Directors for the 2026-2029 four-year term
-
Online Marketing Agency For Lawyers Opens New Office In Sacramento CA
-
Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
-
Cardano Price Prediction: Node 11.0 Upgrade Nears as AlphaPepe Builds Product-Proof Presale Demand
-
Banqup delivers 40,3% y/y growth in subscription revenue in Q1 2026
-
Daytona International Speedway to Install State-of-the-Art Musco LED Lighting System, Setting New Global Standard for Motorsports Venues
-
The Math Underlying the Success of Tort Reforms – Florida Property Insurance and Beyond
-
AMSC to Report Fourth Quarter and Fiscal Year 2025 Financial Results on May 27, 2026
